1. Home
  2. ALLO vs FVCB Comparison

ALLO vs FVCB Comparison

Compare ALLO & FVCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • FVCB
  • Stock Information
  • Founded
  • ALLO 2017
  • FVCB 2007
  • Country
  • ALLO United States
  • FVCB United States
  • Employees
  • ALLO N/A
  • FVCB N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • FVCB Major Banks
  • Sector
  • ALLO Health Care
  • FVCB Finance
  • Exchange
  • ALLO Nasdaq
  • FVCB Nasdaq
  • Market Cap
  • ALLO 252.9M
  • FVCB 240.3M
  • IPO Year
  • ALLO 2018
  • FVCB N/A
  • Fundamental
  • Price
  • ALLO $1.13
  • FVCB $13.30
  • Analyst Decision
  • ALLO Strong Buy
  • FVCB Buy
  • Analyst Count
  • ALLO 10
  • FVCB 1
  • Target Price
  • ALLO $8.88
  • FVCB $16.00
  • AVG Volume (30 Days)
  • ALLO 3.0M
  • FVCB 37.0K
  • Earning Date
  • ALLO 11-06-2025
  • FVCB 10-21-2025
  • Dividend Yield
  • ALLO N/A
  • FVCB 1.78%
  • EPS Growth
  • ALLO N/A
  • FVCB 359.39
  • EPS
  • ALLO N/A
  • FVCB 1.11
  • Revenue
  • ALLO N/A
  • FVCB $62,780,000.00
  • Revenue This Year
  • ALLO N/A
  • FVCB $10.08
  • Revenue Next Year
  • ALLO $100.00
  • FVCB $7.22
  • P/E Ratio
  • ALLO N/A
  • FVCB $12.17
  • Revenue Growth
  • ALLO N/A
  • FVCB 40.73
  • 52 Week Low
  • ALLO $0.86
  • FVCB $9.49
  • 52 Week High
  • ALLO $3.78
  • FVCB $14.50
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 47.86
  • FVCB 51.28
  • Support Level
  • ALLO $1.09
  • FVCB $13.20
  • Resistance Level
  • ALLO $1.21
  • FVCB $13.60
  • Average True Range (ATR)
  • ALLO 0.07
  • FVCB 0.29
  • MACD
  • ALLO 0.01
  • FVCB -0.03
  • Stochastic Oscillator
  • ALLO 33.33
  • FVCB 34.47

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About FVCB FVCBankcorp Inc.

FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, FVCbank which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.

Share on Social Networks: